Use of Imaging Biomarkers for Regulatory Studies

Steiger, Peter
February 2009
Journal of Bone & Joint Surgery, American Volume;Feb2009 Supplement 1, Vol. 91-A Issue S1, p132
Academic Journal
Imaging often plays an important role in pivotal clinical trials of drugs or devices that have been submitted for approval to regulatory agencies that grant approval for the marketing and sale of these products on the basis of documentation of their safety and efficacy. Imaging biomarkers can help substantiate either or both of these characteristics. This article focuses on how to successfully incorporate imaging biomarkers into clinical trials through a process of careful planning and diligent execution. Planning starts with posing and then answering a number of questions that pertain to the product under study. What will the claimed benefit of the product be? Is there a current standard of care that involves imaging, and will that standard of care help in the documentation of safety and efficacy? Are there relevant novel imaging biomarkers? Are there any relevant guidance documents issued by the regulatory agencies? After imaging biomarkers are identified, their role and benefit must be understood. Will they help diagnose subjects? Will they stratify subjects for enrollment? Will they identify those who are more likely to benefit? Will they help document progression of disease and effectiveness of intervention? Execution must occur in close collaboration with regulatory agencies and with the involvement of imaging experts and imaging core laboratories to ensure attention to key components: imaging charter, investigator training and certification, 21 CFR Part 11 (Part 11 of Title 21 of the U.S. Code of Federal Regulations)-compliant data management, real-time incoming image quality control for eligibility reads and investigator feedback, and centralized image analysis for safety and efficacy by certified readers.


Related Articles

  • Global clinical trial laboratories decentralize. Rosenberg, Ronald // CenterWatch Monthly;Apr2014, Vol. 21 Issue 4, p1 

    The article reports that central laboratories which have played an important role in drug development, are now looking for decentralization and regional labs are becoming more active in global clinical trials. With sponsors seeking real-time data access and faster results, labs are conducting...

  • Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease. Zetterberg, Henrik; Mattsson, Niklas; Blennow, Kaj; Olsson, Olsson // Alzheimer's Research & Therapy;2010, Vol. 2 Issue 6, p1 

    In a slowly progressive disorder like Alzheimer disease, evaluation of the clinical effect of novel drug candidates requires large numbers of patients and extended treatment periods. Current cell- and animal-based disease models of Alzheimer disease are poor at predicting a positive treatment...

  • Ensuring Reliable Pulmonary Safety Assessment for the Development of Technosphere®/Insulin (T/I). Harris, Russell; Blonshine, Susan; Baughman, Robert // Diabetes;Jun2007 Supplement 1, Vol. 56, pA535 

    Offering a surface area of up to 100 m², a thin absorptive mucosal membrane and ample blood supply, the pulmonary system has become a route of increased interest for therapeutic delivery. Determination of any alteration in pulmonary function is critical in evaluating the safety of medications...

  • OUTCOMES FOR DISEASE MODIFYING TRIALS. Wilcock, G. // Journal of Nutrition, Health & Aging;Jul/Aug2007, Vol. 11 Issue 4, p318 

    The article discusses the importance of clinical outcomes for Alzheimer's disease (AD) modifying drug trials. It notes that a randomized, parallel, two arm placebo-controlled design is the preferred approach because of its trial duration that shows balance between the time required to manifest a...

  • The Role of Tumor Tissue Architecture in Treatment Penetration and Efficacy: an Integrative Study. Rejniak, Katarzyna A.; Estrella, Veronica; Chen, Tingan; Cohen, Allison S.; Lloyd, Mark C.; Morse, David L. // Frontiers in Oncology;Apr2013, preceding p1 

    Despite the great progress that has been made in understanding cancer biology and the potential molecular targets for its treatment, the majority of drugs fail in the clinical trials. This may be attributed (at least in part) to the complexity of interstitial drug transport in the patient's...

  • PII-47. Liang, Q.; Muhammad, R.; Kapur, S.; Roethig, H.; Sarkar, M. // Clinical Pharmacology & Therapeutics;Feb2006, Vol. 79 Issue 2, pP48 

    Background: This research was conducted to develop models for estimating the amount excreted over a 24-hour period (AE24H) from spot urine (SU) for biomarkers of exposure to smoke constituents.Methods: Thirty-seven adult smokers (females and males) were enrolled into the study and confined for...

  • The potential and limits for clinical trials for early Alzheimer’s disease and some recommendations. SCHNEIDER, L. S. // Journal of Nutrition, Health & Aging;Apr2010, Vol. 14 Issue 4, p295 

    Recommendations for clinical trials methods for ‘pre-dementia,’ ‘prodromal,’ or early Alzheimer’s disease are discussed. Early AD can be considered as subsets of both ‘amnestic MCI’ and ‘probable AD.’ In principle, it can be...

  • The development and potential clinical utility of biomarkers for HDAC inhibitors. Baowen Shi; Wenfang Xu // Drug Discoveries & Therapeutics;2013, Vol. 7 Issue 4, p129 

    Drug discovery has always been a complex process including many phases from target validation to clinical development. Data from the Food and Drug Administration (FDA) has estimated that the elimination rate for investigational new drugs entering clinical trials is up to 80%. In recent years,...

  • TRY TO REMEMBER. Belden, Heidi // Drug Topics;1/22/2007, Vol. 151 Issue 2, p28 

    The article discusses treatment and better disease identification aim to understand Alzheimer's disease (AD). The author reflects that although there is no cure for AD, causes of AD is being identified and new treatments that aim to destroy the buildup of amyloid plaques in the brain are being...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics